Matthew C. Hill is CFO at PDS Biotechnology Corp (PDSB). They have made 6 open-market trades across 4 companies since 2008, most recently 2024-08-13.
CIK 0001278675
6 open-market purchases totalling $68K since 2008, never a sale. Across 5 scored buys the stock is up 12.3% at ninety days, and 8.9 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 20% | 60% |
| Avg Move | +0.4% | -8.7% | +12.3% |
| Alpha | +0.1% | -9.2% | +8.9% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| APYX | BUY | 2024-08-13 | 2024-08-13 | $1.13 | $6K | +15.0% | +9.7% | +31.0% |
| APYX | BUY | 2024-08-13 | 2025-03-03 | $1.13 | $7K | -21.3% | -6.9% | +22.6% |
| APYX | BUY | 2023-12-12 | 2023-12-14 | $2.19 | $5K | +3.0% | -16.1% | -25.8% |
| PDSB | BUY | 2021-12-13 | 2021-12-14 | $8.99 | $27K | -5.8% | -24.3% | -42.5% |
| SSKN | BUY | 2018-06-14 | 2018-06-14 | $1.96 | $20K | +10.8% | -5.7% | +76.3% |
| VLCR | BUY | 2008-05-28 | 2008-05-28 | $0.40 | $4K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.